4 not yet recruiting, 4 unknown, 3 completed, 1 active not recruiting. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Not yet recruiting 4, Unknown 4, Completed 3, Active not recruiting 1, Recruiting 1 |
Follow Ischemic Stroke, Acute: new trials by email Literature Review of Ischemic Stroke, Acute trials Research Report on Ischemic Stroke, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke Lumbrokinase, Lumbrokinase Placebo - Ischemic Stroke, Acute | Phase 4 | Not yet recruiting | Xinqiao Hospital of Chongqing | 1196 | 2026-11-01 | 2026-08-13 |
| Tirofiban Combined With Aspirin in Moderate Ischemic Stroke Tirofiban, Tirofiban-matching placebo - Ischemic Stroke, Acute | Phase 4 | Not yet recruiting | Xinqiao Hospital of Chongqing | 1168 | 2026-10-01 | 2026-08-12 |
| TeleStroke-Guided Thrombolysis for Acute Ischemic Stroke in Oman alteplase or tenecteplase - Ischemic Stroke, Acute, Ischemic Stroke | Phase 4 | Not yet recruiting | Oman Ministry of Health | 200 | 2026-08-01 | 2026-07-22 |
| A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy edaravone dexborneol injection, Standard therapeutic protocol - Ischemic Stroke, Acute, Active Malignancies | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 144 | 2026-08-01 | 2026-04-16 |
| Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes Oral lumbrokinase DLBS1033, Placebo - Ischemic Stroke, Acute | Phase 4 | Completed | Universitas Sebelas Maret | 52 | 2024-07-06 | 2026-10-14 |
| MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure Mexidol - Ischemic Stroke, Acute | Phase 4 | Completed | Pharmasoft | 60 | 2023-04-17 | 2025-04-27 |
| Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B) Minocycline - Ischemic Stroke, Acute, Minocycline | Phase 4 | Active not recruiting | Xijing Hospital | 90 | 2023-03-04 | 2025-05-30 |
| Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA), Best Medical Management - Ischemic Stroke, Acute | Phase 4 | Unknown | Beijing Tiantan Hospital | 256 | 2023-02-16 | 2024-03-19 |
| Safety and Efficacy of Evolocumab in Ischemic Stroke Evolocumab - Ischemic Stroke, Acute | Phase 4 | Unknown | Second Affiliated Hospital of Guangxi Medical University | 200 | 2023-02-01 | 2023-01-25 |
| Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke Cerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysin - Ischemic Stroke, Acute, Diabetes Mellitus, Type 2 | Phase 4 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 60 | 2022-11-17 | 2024-02-22 |
| Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy Minocycline - Ischemic Stroke, Acute | Phase 4 | Completed | Xijing Hospital | 189 | 2022-11-01 | 2026-07-29 |
| Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke Xingnaojing injection - Ischemic Stroke, Acute | Phase 4 | Unknown | Ying Gao | 20 | 2022-08-16 | 2022-09-29 |
| The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional) Blue light exposure + Melatonin treatment, Melatonin treatment, Blue light exposure - Ischemic Stroke, Acute, Sleep Disorders, Circadian Rhythm | Phase 4 | Recruiting | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | 80 | 2022-03-01 | 2025-08-08 |
Ischemic Stroke (13) · Stroke (3) · cyclopia sequence (2) · Brain Injuries, Traumatic (1) · Diabetes Mellitus, Type 2 (1) · Sleep Disorders, Circadian Rhythm (1)
Brain Diseases (13) · Cardiovascular Diseases (13) · Central Nervous System Diseases (13) · Cerebrovascular Disorders (13) · Nervous System Diseases (13) · Vascular Diseases (13) · Stroke (10) · Brain Injuries (1) · Chronobiology Disorders (1) · Craniocerebral Trauma (1) · Diabetes Mellitus (1) · Dyssomnias (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Mental Disorders (1)
Minocycline (2) · Tenecteplase (1) · Tirofiban (1) · Tissue Plasminogen Activator (1) · cerebrolysin (1) · emoxypine succinate (1) · ethylmethylhydroxypyridine succinate (1) · evolocumab (1) · lumbrokinase (1) · xingnaojing (1)
Xijing Hospital (2) · Xinqiao Hospital of Chongqing (2) · Beijing Tiantan Hospital (1) · Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Nanfang Hospital, Southern Medical University (1) · Oman Ministry of Health (1) · Pharmasoft (1) · Second Affiliated Hospital of Guangxi Medical University (1) · Universitas Sebelas Maret (1) · Ying Gao (1)
China (6) · Russia (2) · Indonesia (1) · Mexico (1)
Zhongming Qiu (2) · Arunodaya R Gujjar, MD, DM, FRCP (1) · Firstiafina Tiffany, MD (1) · Junli Liang, PhD (1) · Lyudmila Korostovtseva (1) · Sanjay Jaju, MD (1)
PMID 39357896, PMID 39764289, PMID 39806586, PMID 40616323, PMID 42305108